Precigen (PGEN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Apr, 2026Executive summary
Annual meeting scheduled for June 18, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 17, 2026.
Voting matters and shareholder proposals
Election of nine directors is proposed, with all nominees recommended by the board.
Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) is included.
Approval sought for an amendment to the 2023 Omnibus Incentive Plan.
Proxies may vote on other business arising at the meeting.
Board of directors and corporate governance
Board recommends all director nominees for election.
Director nominees include Randal Kirk, Cesar Alvarez, Steven Frank, Vinita Gupta, Fred Hassan, Jeffrey Kindler, Nancy Howell Agee, Helen Sabzevari, and James Turley.
Latest events from Precigen
- Q2 2026 profitability reached as PAPZIMEOS revenue soared to $53.1M and adoption accelerated.PGEN
Q2 2026 - All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions.PGEN
AGM 2026 - Rapidly approved gene therapy for RRP sees strong uptake and expansion into new markets.PGEN
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - PAPZIMEOS launch drove $21.6M Q1 revenue, rapid adoption, and a sharply narrowed net loss.PGEN
Q1 2026 - Shareholders will vote on director elections, auditor ratification, executive pay, and a key equity plan amendment.PGEN
Proxy filing - PAPZIMEOS sets a new standard for RRP, fueling growth and pipeline expansion via a unique platform.PGEN
Fireside chat - PAPZIMEOS launch accelerates revenue growth and adoption, with Q1 2026 revenue set to exceed $18M.PGEN
Q4 2025 - PRGN-2012 pivotal data and cost cuts drive focus as net loss widens and FDA submission nears.PGEN
Q2 2024 - 51% complete response and 86% surgery reduction achieved, with durable efficacy and strong safety.PGEN
Study Result